Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivonescimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07590531 is registered in ClinicalTrials.gov with Multitude Therapeutics Inc. as lead sponsor.

NCT NCT07590531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07590531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivonescimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Multitude Therapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 29, 2026
Completion date
December 31, 2027
Enrollment
118 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer (nsclc)